This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Rifadin
- Starting date:
- February 26, 2013
- Posting date:
- March 19, 2013
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type II
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-25899
Recalled Product
A. Rifadin
Reason
Manufacturer testing revealed out-of-specification fill weight results in retention samples for Rifadin 150mg capsules from batch 3099036.
Depth of distribution
Wholesalers and pharmacies
Affected products
A. Rifadin
DIN, NPN, DIN-HIM
DIN 02091887Dosage form
Capsule
Strength
150 mg / capsule
Lot or serial number
Lot 3099036
Companies
- Recalling Firm
-
Sanofi Aventis (Canada) Inc.
2905 Louis R. Renaud Place
Laval
H7V 0A3
Quebec
CANADA
- Marketing Authorization Holder
-
Sanofi Aventis (Canada) Inc.
2905 Louis R. Renaud Place
Laval
H7V 0A3
Quebec
CANADA